Almac rolls out direct-to-patient service in Europe

By Gareth Macdonald contact

- Last updated on GMT

Almac launches delivery service in Europe
Almac launches delivery service in Europe

Related tags: Europe, North america, European union

Almac has launched its trial drug home delivery service in Europe citing demand it has seen since rolling out the service in North America.

The direct-to-patient (DTP) service, as the name suggests, ships trial drugs to the homes of people taking part in studies with the idea being that reducing the number of visits participants need to make to research sites reduces drop-out and improves compliance.

Almac launched DTP in the US and Canada last year and the decision to roll it out in Europe reflects how popular it has been with customers in North America according to a spokeswoman for the Northern Ireland-based contractor.

She told us the firm has “experienced increasing demand for this service with a number of solid enquiries and live protocols in the US and Canada in the States​” but declined to name the customers involved.

The offering – which falls under the remit of Almac’s clinical services group – is being made available in the UK, Germany, Spain, Poland, Italy, Hungary, France, Czech Republic, Bulgaria, Romania, Belgium and the Netherlands the spokesman continued, explaining that shipping is a two-step process.

The drug is always shipped to site and then couriered to the patient home from site. Customers can only use the service if they have submitted a DTP request in the study submissions therefore the service can only be used in new studies moving forward​.”

Patient-centric clinical trials are a hot topic for sponsors and the contract services sector at the moment.

In April​, industry think tank Transcelerate Biopharma said it was using the concept of ‘patient centricity’ ​and connectivity to influence the clinical trial environment.

Related news

Show more

Related products

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us


View more